Fmoc-ADMA(Pbf)-OH

Description

• General description: A derivative for the introduction of asymmetric dimethyl-arginine during Fmoc SPPS. Coupling can be carried out using any standard activation method. Removal of the Pbf protecting group occurs during the course of the TFA-mediated cleavage reaction. Ref [1] contains methods and protocols for the synthesis of arrays of histone-related peptides containing methylated arginine and lysine-residues. Associated Protocols and Technical ArticlesCleavage and Deprotection Protocols for Fmoc SPPSLiterature references[1] S. Rothbart, et al. (2012) Methods Enzymol., 512, 107.
• Application: Effect of arginine methylation on the RNA recognition and cellular uptake of Tat-derived peptides: Studies the use of Fmoc-ADMA(Pbf)-OH in modifying peptides to enhance their cellular uptake, relevant for drug delivery systems and therapeutic molecule development (JH Li et al., 2015). Advances in Fmoc solid-phase peptide synthesis: Reviews the role of Fmoc-ADMA(Pbf)-OH in advancing peptide synthesis techniques, impacting the field of material science through the development of novel synthetic strategies and applications in biomaterials (R Behrendt, J Offer, 2016).
• Linkage: Replaces: 04-12-1264
• Analysis Note: Color (visual): white to slight yellow to beigeAppearance of substance (visual): powderIdentity (IR): passes testPurity (TLC(157A)): ≥ 98 %Enantiomeric purity: ≥ 99.0 % (a/a)Assay (HPLC, area%): ≥ 96.0 % (a/a)Solubility (1 mmole in 2 ml DMF): clearly solubleWater (K. F.): ≤ 2.0 %To see the solvent systems used for TLC of Novabiochem® products please click here.
• Legal Information: Novabiochem is a registered trademark of Merck KGaA, Darmstadt, Germany